AI-Immunology™ We strive to develop novel drugs with an unprecedented level of efficacy and precision. Using AI, we simulate the human immune system and generate predictive models to identify and develop personalized and other next-generation immunotherapies for patients.

ONCOLOGY

PIONEER™ is a proprietary AI-Immunology™ model for the rapid discovery of patient-specific neoantigens used for our personalized cancer immunotherapies. We want to challenge and improve the standardized therapies of today, where one size fits all, risking unspecific immune activation. With our AI-Immunology™ platform, we seek out and target cancer cells, creating truly personalized therapies where one size fits one and only one.

Related Press Releases

""

Apr 2, 2024

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

""

Mar 19, 2024

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
""

Feb 20, 2024

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

""

Jan 24, 2024

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

""

Nov 28, 2023

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

""

Nov 15, 2023

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.